Isoquercetin Combination Therapy for Sickle Cell Vasculopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease are inadequate in effectively managing the thrombo-inflammatory vasculopathy associated with crescent-shaped red blood cells, which cause blockages and impair blood flow.
Innovation Solution
Administering a combination of isoquercetin, vitamin B3, and vitamin C, optionally with folic acid, to synergistically reduce symptoms and progression of sickle cell disease by inhibiting extracellular protein disulfide isomerase (PDI) and modulating neutrophil recruitment and platelet activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for sickle cell disease, then basic symptom management is achieved, but the thrombo-inflammatory vasculopathy is not effectively managed
Solution Approach 1:
The patent combines multiple active ingredients (quercetin, vitamin B3, vitamin C, and optionally folic acid) into a single pharmaceutical composition. This combination approach allows synergistic effects where the sum of the individual components produces a greater therapeutic effect than each component alone, thereby effectively managing thrombo-inflammatory vasculopathy that cannot be achieved by conventional single-agent treatments.
Solution Approach 2:
The invention uses a composite pharmaceutical composition containing multiple bioactive compounds with different mechanisms of action. Quercetin provides anti-inflammatory and antioxidant effects, vitamin B3 modulates lipid metabolism and inflammation, vitamin C enhances antioxidant capacity, and folic acid supports red blood cell production. This composite formulation addresses the complex pathophysiology of sickle cell disease more comprehensively than conventional treatments.
2Ease of manufacture
If individual components are administered separately, then simplicity of formulation is maintained, but therapeutic benefit is reduced
Solution Approach 1:
The patent merges multiple active ingredients into a single pharmaceutical composition that can be manufactured and administered as one unit. This unified formulation simplifies the manufacturing process compared to producing and coordinating multiple separate medications, while simultaneously providing enhanced therapeutic benefit through synergistic interactions between the components.
Solution Approach 2:
The pharmaceutical composition is designed to perform multiple therapeutic functions simultaneously: quercetin addresses inflammation and oxidative stress, vitamin B3 manages lipid metabolism and inflammation, vitamin C provides antioxidant protection, and folic acid supports hemoglobin synthesis. This multi-functional formulation achieves greater therapeutic benefit while maintaining formulation simplicity.
Data Source
AI summary
Disclosed are compositions and methods for treating sickle cell disease. Also disclosed are methods of treating sickle cell disease comprising administering to a subject in need thereof an effective amount of isoquercetin, vitamin B3, vitamin C, and optionally folic acid and wherein the effective amount is sufficient to halt progression of one or more of the symptoms of sickle cell disease.